Goldman Sachs Group Inc Impel Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$5.78 - $9.32 $17,715 - $28,565	-3,065 Reduced 21.46%	11,220 $55,000
Q3 2022 Nov 10, 2022	SELL	$5.78 - $9.32 $17,715 - $28,565	-3,065 Reduced 21.46%	11,220 $0
Q2 2022 May 14, 2024	BUY	$5.83 - $10.12 $83,281 - $144,564	14,285 New	14,285 $133,000
Q2 2022 Aug 15, 2022	BUY	$5.83 - $10.12 $8,651 - $15,018	1,484 Added 11.59%	14,285 $133,000
Q1 2022 May 16, 2022	BUY	$5.86 - $9.85 $12,388 - $20,822	2,114 Added 19.78%	12,801 $82,000
Q4 2021 Feb 14, 2022	BUY	$8.33 - $12.14 $89,022 - $129,740	10,687 New	10,687 $92,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.